FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2515013664> ?p ?o ?g. }

• W2515013664 endingPage "28" @default.
• W2515013664 startingPage "21" @default.
• W2515013664 abstract "Angiogenesis occurs in response to tissue ischemia and wound healing, and contributes to the pathogenesis of a variety of diseases, such as benign and malignant neoplasia. Several studies have measured bone marrow microvessel density (MVD) in MDS patients and acute myeloid leukemia (AML) patients transformed from MDS, and MVD was higher in MDS patients than controls, but was lower than in AML patients. Vascular endothelial growth factor (VEGF) is expressed in bone marrow blast cells, and an autocrine VEGF signaling mechanism has been established in MDS. Increased bone marrow angiogenesis and VEGF concentrations are adverse prognostic features in all of these patients. In this study, 69 patients were treated in two groups: hypomethylating agents or supportive care with oxymetholone ± pyridoxine. We evaluated the MVD and VEGF expression of paraffin-embedded bone marrow samples from patients. We also investigated the relationship between angiogenesis-related biomarkers including MVD, VEGF expression, and clinical factors. The patient median age was 65 years, and the median follow-up duration was 28 months. MVD assessment among subtypes of WHO MDS classification showed that the MVD of RCUD was significantly lower than in other types (p = 0.02). However, there was no significant difference in VEGF expression according to the subtype of MDS. Although MVD and VEGF expression did not differ between risk groups based on the IPSS, the low risk group tended to have lower expression of angiogenesis-related biomarkers. MDS patients receiving hypomethylating agents had significantly lower MVD expression in responders than in non-responders (6.13 ± 3.38 vs. 9.89 ± 2.10, respectively, p = 0.039). In a consecutive evaluation at the time of diagnosis and 3 months after the initial treatment, the group with a decrease or no change of MVD had a higher response rate compared to that in the group with an increase of MVD (92.9% vs. 58.8%, respectively, p = 0.045). Adverse prognostic factors included older age, MDS type other than RCUD, a higher IPSS risk group, and abnormal cytogenetics. Although angiogenesis-related markers did not demonstrate any significant prognostic association with survival, MVD (≥10 n/mm2) and a strong expression of VEGF seemed to be associated with lower survival rate. These data suggested that the MVD value might be helpful in predicting responsiveness to treatment, especially in MDS patients treated with hypomethylating agents. Although angiogenesis-related markers including VEGF did not demonstrate a significant association with survival outcomes, we observed that high MVD and strong VEGF expression seemed to be associated with lower survival rate. Therefore, biologic markers related to angiogenesis might have a potential as prognostic factors for MDS patients." @default.
• W2515013664 created "2016-09-16" @default.
• W2515013664 creator A5001027928 @default.
• W2515013664 creator A5020726281 @default.
• W2515013664 creator A5024677686 @default.
• W2515013664 creator A5028902149 @default.
• W2515013664 creator A5041723605 @default.
• W2515013664 creator A5047621773 @default.
• W2515013664 creator A5062704344 @default.
• W2515013664 creator A5066039159 @default.
• W2515013664 creator A5071291362 @default.
• W2515013664 creator A5071881182 @default.
• W2515013664 creator A5076918008 @default.
• W2515013664 creator A5085596906 @default.
• W2515013664 creator A5086393428 @default.
• W2515013664 creator A5086526948 @default.
• W2515013664 date "2016-11-01" @default.
• W2515013664 modified "2023-09-27" @default.
• W2515013664 title "Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents" @default.
• W2515013664 cites W1569016295 @default.
• W2515013664 cites W187238933 @default.
• W2515013664 cites W1967615994 @default.
• W2515013664 cites W1978139448 @default.
• W2515013664 cites W1988327939 @default.
• W2515013664 cites W2003562932 @default.
• W2515013664 cites W2011413594 @default.
• W2515013664 cites W2028777177 @default.
• W2515013664 cites W2030383017 @default.
• W2515013664 cites W2038448524 @default.
• W2515013664 cites W2057103712 @default.
• W2515013664 cites W2084816666 @default.
• W2515013664 cites W2084944550 @default.
• W2515013664 cites W2085266690 @default.
• W2515013664 cites W2088111660 @default.
• W2515013664 cites W2107398329 @default.
• W2515013664 cites W2127240439 @default.
• W2515013664 cites W2129510594 @default.
• W2515013664 cites W2129684262 @default.
• W2515013664 cites W2142960171 @default.
• W2515013664 cites W2144026946 @default.
• W2515013664 cites W2160377294 @default.
• W2515013664 cites W2163751036 @default.
• W2515013664 cites W2166506757 @default.
• W2515013664 cites W226609814 @default.
• W2515013664 cites W2394519452 @default.
• W2515013664 cites W331857686 @default.
• W2515013664 cites W4367435856 @default.
• W2515013664 doi "https://doi.org/10.1016/j.leukres.2016.08.012" @default.
• W2515013664 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27639703" @default.
• W2515013664 hasPublicationYear "2016" @default.
• W2515013664 type Work @default.
• W2515013664 sameAs 2515013664 @default.
• W2515013664 citedByCount "10" @default.
• W2515013664 countsByYear W25150136642018 @default.
• W2515013664 countsByYear W25150136642019 @default.
• W2515013664 countsByYear W25150136642020 @default.
• W2515013664 countsByYear W25150136642021 @default.
• W2515013664 crossrefType "journal-article" @default.
• W2515013664 hasAuthorship W2515013664A5001027928 @default.
• W2515013664 hasAuthorship W2515013664A5020726281 @default.
• W2515013664 hasAuthorship W2515013664A5024677686 @default.
• W2515013664 hasAuthorship W2515013664A5028902149 @default.
• W2515013664 hasAuthorship W2515013664A5041723605 @default.
• W2515013664 hasAuthorship W2515013664A5047621773 @default.
• W2515013664 hasAuthorship W2515013664A5062704344 @default.
• W2515013664 hasAuthorship W2515013664A5066039159 @default.
• W2515013664 hasAuthorship W2515013664A5071291362 @default.
• W2515013664 hasAuthorship W2515013664A5071881182 @default.
• W2515013664 hasAuthorship W2515013664A5076918008 @default.
• W2515013664 hasAuthorship W2515013664A5085596906 @default.
• W2515013664 hasAuthorship W2515013664A5086393428 @default.
• W2515013664 hasAuthorship W2515013664A5086526948 @default.
• W2515013664 hasConcept C104317684 @default.
• W2515013664 hasConcept C126322002 @default.
• W2515013664 hasConcept C142724271 @default.
• W2515013664 hasConcept C143998085 @default.
• W2515013664 hasConcept C150194340 @default.
• W2515013664 hasConcept C167734588 @default.
• W2515013664 hasConcept C190727270 @default.
• W2515013664 hasConcept C2776012956 @default.
• W2515013664 hasConcept C2777025900 @default.
• W2515013664 hasConcept C2778271429 @default.
• W2515013664 hasConcept C2778729363 @default.
• W2515013664 hasConcept C2779282312 @default.
• W2515013664 hasConcept C2780007613 @default.
• W2515013664 hasConcept C2780394083 @default.
• W2515013664 hasConcept C2780817109 @default.
• W2515013664 hasConcept C55493867 @default.
• W2515013664 hasConcept C71924100 @default.
• W2515013664 hasConcept C86803240 @default.
• W2515013664 hasConcept C90924648 @default.
• W2515013664 hasConceptScore W2515013664C104317684 @default.
• W2515013664 hasConceptScore W2515013664C126322002 @default.
• W2515013664 hasConceptScore W2515013664C142724271 @default.
• W2515013664 hasConceptScore W2515013664C143998085 @default.
• W2515013664 hasConceptScore W2515013664C150194340 @default.
• W2515013664 hasConceptScore W2515013664C167734588 @default.
• W2515013664 hasConceptScore W2515013664C190727270 @default.

• next